Fusion Antibodies (LON:FAB) Posts Earnings Results

Fusion Antibodies (LON:FAB) announced its earnings results on Monday. The company reported GBX (1.20) EPS for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%.

Fusion Antibodies Trading Up 6.0%

Shares of FAB stock opened at GBX 11.40 on Wednesday. The stock has a market cap of £14.27 million, a P/E ratio of -7.60 and a beta of 1.24. Fusion Antibodies has a 1 year low of GBX 9 and a 1 year high of GBX 21. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42. The stock has a 50 day simple moving average of GBX 10.82 and a 200 day simple moving average of GBX 12.14.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.